文献速递胸部肿瘤放疗姑息放疗与转移瘤

奥希替尼治疗转移性EGFR突变NSCLC的复发模式分析:对巩固性SBRT的启示

Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-01-25

进展者中70%为寡进展,且多数进展位于原残留病灶。

要点

  • 最大缓解中位时间2.6个月,26.8%患者为巩固性SBRT候选者
  • 疾病进展者中70%为寡进展,RR占50%、NR占22%、RNR占28%

核心结论

  • 奥希替尼治疗进展多数发生在初始受累部位的残留病灶内。
  • 巩固性SBRT可能在部分筛选患者中延长至进展时间,值得进一步研究。

研究设计与样本

  • 按进展部位分为残留部位复发(RR)、新部位复发(NR)及两者兼有(RNR)。
  • 采用逻辑回归分析筛选巩固性SBRT候选者的预测因素。

主要发现

  • 至奥希替尼最大缓解的中位时间为2.6个月。
  • 26.8%(26例)患者伴寡残留病灶,在最大缓解时被确定为巩固性SBRT候选者。
  • 中位随访10.9个月期间,51.5%(50例)患者记录到疾病进展,其中70%为寡进展。
  • 46例患者在初始稳定或客观缓解后出现进展,其中RR 43.5%(20例)、NR 30.4%(14例)、RNR 26.1%(12例)。

关键数值与推荐

  • 巩固性SBRT候选者亚组中,RR为54.5%(6例)、RNR为27.3%(3例)、NR为18.2%(2例)。

临床怎么用

  • 对奥希替尼治疗最大缓解时的寡残留患者,可评估巩固性SBRT适应性和T1-2期特征。
  • 进展模式以残留部位为主,提示局部巩固治疗可能具有临床价值。

局限性

  • 原文为回顾性研究,未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite the impressive response rate to osimertinib, acquired resistance remains an obstacle to achieving long-term tumor control in metastatic epidermal growth factor receptor-mutant non-small cell lung cancer. Stereotactic body radiation therapy (SBRT) plays a growing role in the management of oligometastatic disease. We investigated the patterns of residual disease and progression on osimertinib, as well as the predictors of candidates for consolidative SBRT. METHODS AND MATERIALS: The serial scans of patients with metastatic epidermal growth factor receptor-mutant non-small cell lung cancer treated with osimertinib were retrospectively reviewed. Disease progression in residual sites, new sites, and both residual and new sites were classified as residual-site recurrence (RR), new-site recurrence (NR), and combined RR and NR (RNR), respectively. Logistic regression analysis was performed to identify predictors of candidates for consolidative SBRT. RESULTS: Ninety-seven patients were enrolled. The median time to maximal osimertinib response was 2.6 months. Twenty-six patients (26.8%) with oligoresidual disease were identified as candidates for consolidative SBRT at time of maximal response. Stage T1-2 before initiation of osimertinib (P = .046) was the independent predictor of consolidative SBRT eligibility. During a median follow-up of 10.9 months, disease progression was documented in 50 (51.5%) patients, and 70% of them experienced oligoprogression. Twenty-five (50%) patients developed disease progression in originally involved sites, 11 (22%) had new metastases, and 14 (28%) experienced disease progression in both original and new metastatic sites. Forty-six patients had progressive disease after experiencing initial stable disease or objective response to osimertinib. RR occurred in 20 (43.5%) of these patients, NR in 14 (30.4%), and RNR in 12 (26.1%). Notably, within the subgroup of patients eligible for consolidative SBRT, RR was observed in 6 (54.5%) patients, RNR in 3 (27.3%), and NR in 2 (18.2%). CONCLUSIONS: The majority of progressive disease on osimertinib was within residual lesions in initially involved sites. Consolidative SBRT may prolong time to progression in a selected subgroup of patients, which merits further investigation.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Guo T, Ni J, Yang X, et al. Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020. PMID: 31987959. doi:10.1016/j.ijrobp.2019.12.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。